Lido Advisors, LLC Cardiff Oncology, Inc. Transaction History
Lido Advisors, LLC
- $31.4 Billion
- Q3 2025
A detailed history of Lido Advisors, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Lido Advisors, LLC holds 14,981 shares of CRDF stock, worth $32,209. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,981
Previous 15,000
0.13%
Holding current value
$32,209
Previous $47,000
36.17%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRDF
# of Institutions
125Shares Held
21.8MCall Options Held
1.11MPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA3.59MShares$7.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.65 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY2.47MShares$5.3 Million0.09% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$4.76 Million0.01% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.96MShares$4.22 Million2.05% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $93.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...